Analyst Yanan Zhu of Wells Fargo maintained a Buy rating on RAPT Therapeutics, reducing the price target to $38.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Yanan Zhu has given his Buy rating due to a combination of factors that suggest potential growth for RAPT Therapeutics. The company’s partner, Jemincare, is expected to release study results in the second half of 2025, which could demonstrate superior pharmacodynamics and efficacy of RPT904 compared to Xolair in related indications. This could lead to a significant increase in the value of RAPT shares.
Additionally, RAPT Therapeutics reported a better-than-expected net loss per share for the second quarter of 2025 and maintains a strong cash position. The company is also progressing with its Phase 2b study for food allergy, with top-line data anticipated in the first half of 2027. These developments, alongside the initiation of a next-generation CCR4 antagonist program, contribute to the positive outlook and the Buy rating from Yanan Zhu.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $27.00 price target.
RAPT’s price has also changed dramatically for the past six months – from $1.160 to $10.250, which is a 783.62% increase.